JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates…
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical…
NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader…
DSMC has reviewed the safety and pharmacokinetic data from Cohort 2 and recommended that the study proceed to enroll patients…
New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE…
LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical…
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting…
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”),…
BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…